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Introduction Despite Mycoplasma genitalium (MG) being increasingly recognised as a 
genital pathogen in men and women, awareness and utility of commercially available MG- 
testing may be low. The opinion of UK sexual health clinicians and allied professionals was 
sought on how MG-testing should be used.   
Methodology Thirty-two consensus statements were developed by an expert group and 
circulated to clinicians and laboratory staff, who were asked to evaluate their level of 
agreement with each statement; 75% agreement was set as the threshold for defining 
consensus for each statement. A modified Delphi approach was used and high levels of 
agreement obviated the need to test the original statement set further. 
Results and Discussion Of 201 individuals who received questionnaires, 60 responded, most 
(48) being sexual health consultants, more than 10% of the total in the UK.  Twenty-seven 
(84.4%) of the statements exceeded the 75% threshold. Respondents strongly supported MG-
testing of patients with urethritis, pelvic inflammatory disease, or unexplained persistent 
vaginal discharge, or post-coital bleeding. Fewer favoured testing patients with proctitis and 
support was divided for routinely testing chlamydia-positive patients. Testing of current 
sexual contacts of MG-positive patients was supported, as was a test of cure for MG-positive 
patients, although agreement fell below the 75% threshold. Respondents agreed that all 
consultant or specialist-led services should have access to testing for MG (98.3%). 
Conclusion There was strong agreement for having MG-testing available for specific patient 
groups, which may reflect concern over antibiotic resistance and the desire to comply with 
clinical guidelines that recommend MG-testing in sexual health clinic settings. 
 




Despite being a recognised genito-urinary (GU) pathogen for two decades in men [1] and 
more recently in women, [2] diagnostic testing has been limited. Molecular assays, both in 
house and CE approved have been available but, until recently, there was no commercial 
assay fully approved by the Food and Drug Administration (FDA). [3, 4] Commercial 
availability of MG-testing presents an opportunity for improving the diagnostic and 
management pathways of several clinical syndromes associated with MG infection, including 
urethritis in men and cervicitis and pelvic inflammatory disease (PID) in women. However 
the process has become complicated because of the rapid emergence of antimicrobial-
resistant MG. [5, 6, 7] Diminishing the risk of increasing macrolide and quinolone resistance 
in MG requires a robust diagnostic and treatment pathway.  
 
The 2016  European MG guidelines [7] recommended  testing for MG in: men with 
symptoms or signs of urethritis or acute epididymo-orchitis if  aged <50 years ; and in 
women with mucopurulent cervicitis, cervical or vaginal discharge with risk factor for 
sexually transmitted infection (STI), and those with intermenstrual or post coital bleeding or 
acute pelvic pain and/or PID. [7] These symptoms and signs are also commonly associated 
with Chlamydia trachomatis and patients when treated syndromically are likely to be 
prescribed azithromycin 1g , which was a recommended first line therapy for chlamydial 
infection until recently. [8-11]  
 
There is, therefore, a clear need to identify MG infection [5] and treat correctly to avoid 
inappropriate or sub-optimal treatment, which is associated with the development of 
resistance. [5] 
The worldwide focus on antimicrobial stewardship must be considered against the 
background of extreme financial pressure which impacts healthcare provision in every 
country. [12] In the United Kingdom, Local Authorities are the funding source for all 
screening and treatment related to sexual health and they must balance the pressure for short-
term cost savings against the long-term cost impacts of undiagnosed or untreated conditions. 
 
The only methodology appropriate for MG diagnosis is a nucleic acid amplification test 
(NAAT). [3,4, 7] Although the optimal treatment for MG is unclear, treatment with 
azithromycin 1g, which is associated with the development of macrolide resistance, is not 
recommended. [6-8, 13] This study assesses the attitudes of clinical professionals involved in 
the diagnosis and management of conditions associated with MG infection in order to make 
appropriate recommendations for best practice. 
METHODOLOGY 
A group of experts in GU medicine and microbiology (the authors of this paper) met in order 
to examine issues facing clinicians in the diagnosis and management of MG infection.  All of 
the group are either currently or were previously involved in MG diagnostic research. 
Discussion identified 6 themes which were Rationale for MG-testing, Selection of Patients, 
Diagnostic Strategy, Cost Effectiveness, Antimicrobial Resistance / Antimicrobial 
Stewardship and Availability of MG-testing. These were then expanded to develop a series of 
32 consensus statements (Table 1). 
 
 
Table 1. Consensus Statements by Theme (n = number of responders, score = percentage of 
respondents in agreement with each statement)   
 
Ref: Topic: Statement: 
n: Score 
(%) 
1 Rationale for M. 
genitalium  testing 
M. genitalium is a proven pathogen for urethritis  in men  59 98.3 
2 M. genitalium may cause symptoms such as urethral 
discharge, dysuria and urethral discomfort in men 
60 100 
3 Effective targeted treatment for M. genitalium is available 
and may differ from standard urethritis treatment 
60 93.3 
4 M. genitalium is a proven pathogen for cervicitis and may 
be associated with post coital bleeding 
59 89.8 
5 M. genitalium is a proven pathogen for PID in women 59 83.1 
6 M. genitalium is a proven but uncommon pathogen for 
vaginal discharge and irritation in women 
60 56.7 
7 M. genitalium is a proven pathogen for proctitis in MSM 57 56.1 
8 Selection of 
Patients 
Men with symptoms suggestive of urethritis should be 
tested for chlamydia, gonorrhoea and M. genitalium 
60 85 
9 Asymptomatic patients should not be tested for M. 
genitalium 
60 76.7 
10 Current sexual contacts of those with confirmed M. 
genitalium should be tested regardless of symptoms 
60 81.7 
11 Women with a clinical diagnosis of PID should be tested for 
chlamydia, gonorrhoea and M. genitalium 
60 78.3 
12 MSM presenting with proctitis should be tested using NAAT 
for chlamydia, gonorrhoea, herpes and M. genitalium 
60 65 
13 Testing for M. genitalium should be considered in women 
with unexplained, persistent vaginal discharge 
59 79.7 





Where possible all men with symptoms of urethritis should 
be assessed with urethral microscopy 
60 95 
16 Where possible all men with symptoms of urethritis should 
be tested for chlamydia, gonorrhoea and M. genitalium 
concurrently 
59 84.7 
17 Where possible all men with confirmed urethritis on 
microscopy should be tested for chlamydia, gonorrhoea and 




It is likely that targeted testing of symptomatic patients for 
M. genitalium will be cost effective 
59 81.4 
19 It is unlikely that testing asymptomatic patients for M. 
genitalium will be cost effective 
58 82.8 
20 More evidence is needed regarding the cost effectiveness 






Individuals identified as M. genitalium positive should have 
a test of cure performed to confirm clearance 
60 68.3 
22 Confirmed M. genitalium should be treated specifically 
according to the result of any resistance testing or the 
knowledge of local resistance patterns 
60 98.3 
23 Detection of any macrolide resistance will assist with the 
selection of prescribed therapy and likelihood of clearance 
60 98.3 
24 Treatment of M. genitalium should proceed irrespective of 
the availability of resistance testing 
60 78.3 
25 Antimicrobial stewardship is important and best informed by 
resistance testing 
60 98.3 
26 Detection of quinolone resistance may assist with the 
specificity of prescribed therapy and likelihood of clearance 
60 90 
27 Moxifloxacin should be reserved for those with a confirmed 
diagnosis of M. genitalium 
59 93.2 
28 M. genitalium infection (where  antibiotic resistance status 
is not known) should be treated with azithromycin 500mgs 
then 250mgs for 4 days 
58 93.1 
 While the author group developed the initial consensus statements, the involvement of a 
wider audience reflecting the views of key stakeholders across the UK was sought in order to 
develop a more robust and representative consensus view. To achieve this, the statements 
were circulated by questionnaire to the following groups: Clinical and laboratory colleagues 
of the author group (41 in number), Bacterial Special Interest Group of the British 
Association of Sexual Health & HIV (BASHH)  mailing list (19, who forwarded it to a 
further 28), all consultants in sexual health in South West England (23),  Laboratory 
personnel by Hologic user network  (36 laboratories; 32% of laboratories in the UK) and UK 
Clinical Virology Network members (54 individuals viewed the questionnaire from 48 
laboratories). Thus it is calculated that 201 individual workers received a questionnaire. 
In order to define consensus, a modified Delphi methodology was used. [14] This approach 
works through written feedback, in order to measure consensus or agreement where differing 
opinions may exist. The level of individual agreement with each statement was measured 
using a 4-point Likert scale, which allows delegates to record levels of agreement or 
disagreement with each statement. Whilst the four point Likert scale allowed respondents to 
vary their level of agreement or disagreement (strongly or weakly), responses were 
interpreted in a binary fashion as either agreement or disagreement according to the Delphi 
29 Men with NGU found to be M. genitalium positive with 
persistent urethritis following doxycycline treatment should 
be treated with a combination of azithromycin 500mgs then 
250mgs for 4 days and metronidazole 400mgs bd 5 days. 
58 77.6 
30 Use of azithromycin 1g stat is likely to lead to high levels of 
macrolide resistance in M. genitalium and should be 
avoided where possible 
59 94.9 
31 Availability of M. 
genitalium testing 
All level 3 GUM clinics in the UK should have access to M. 
genitalium testing 
59 98.3 
32 All level 3 GUM clinics in the UK should have access to M. 
genitalium resistance testing 
59 96.6 
process. Following review of the responses as numbers increase, the process allows the 
modification of each statement if necessary in order to increase the level of agreement and 
therefore represent the majority view of respondents. In order to ensure that feedback was 
reviewed, the questionnaires were assessed as they were received. The levels of agreement 
with each statement were monitored by the group, who concluded that due to the high levels 
of agreement (84.4%) achieved by most statements, the requirement to modify the statements 
was obviated. 
Reflecting best practice, an agreement threshold of 75% was considered for each statement as 
demonstrating consensus. [15, 16] 
RESULTS 
Of 201 individual recipients, sixty respondents from various UK localities returned 
completed questionnaires – a response rate of 29.8%. Overall, 27 (84.4%) of the statements 
achieved greater than 75% agreement with 19 (59.4%) achieving greater than 90% agreement 
across the respondent group. Five of the statements (15.6%) failed to meet the 75% 
agreement threshold (Table 1). Of the 60 completed questionnaires received back from 
respondents, the majority (48) were from sexual health consultants. The remainder were from 
consultants in Microbiology (2), Gynaecology (1), and Urology (1), in addition to responses 
from Laboratory personnel (2), Specialist Nurses (3), other disciplines (1) and two being of 
unknown discipline.This sample of sexual health consultants represents approximately 12% 
of the population in the UK, estimated to be 400 in number. [18]  
Respondents indicated strong support for identification and effective targeted treatment of 
MG as detailed below and in Table 1. 
Rationale for MG-testing 
Respondents indicated strong consensus regarding the role of MG as a pathogen causing 
urethritis in men. There was less agreement regarding MG as a cause of discharge in women 
and proctitis in MSM, which may indicate a need for further evidence. 
Selection of Patients 
Strong agreement with all but two of the statements in this section of the questionnaire 
reflects the current evidence base. Respondents agreed that women with unexplained 
persistent vaginal discharge should be tested for MG, but did not appear as confident that MG 
is a proven pathogen in this respect. 
Diagnostic Strategy 
Respondents strongly supported all three statements in this section. There was agreement by 
84.7% of respondents that all men presenting with symptoms of urethritis or in whom 
urethritis is confirmed by microscopy should be tested for MG, C. trachomatis and Neisseria 
gonorrhoeae concurrently. 
Cost Effectiveness 
Most respondents believed targeted testing of symptomatic patients to be cost effective. 
Equally, respondents believed that asymptomatic screening may not be cost effective.  
Antimicrobial Resistance / Antimicrobial Stewardship 
Respondents strongly supported most of the statements within this section of the 
questionnaire. Only the assertion that patients tested as MG-positive should have a test of 
cure performed to confirm clearance failed to meet the 75% consensus threshold. 
Availability of MG-testing 
The statements that MG-testing and resistance testing should be available to all level 3 clinics 
were strongly supported by respondents. 
 
DISCUSSION 
A series of statements regarding MG- testing and treatment have been identified and were 
strongly supported by respondents to the questionnaire indicating the increasing importance 
of M. genitalium as a pathogen.  
However, a limitation of this study is that there was a dominance of sexual health consultants 
among the respondents which is initially surprising as questionnaires were offered to a broad 
range of associated specialties including gynaecology and urology. This could suggest that 
the existence of MG is not well known outside sexual health clinical practice and as a 
consequence, non- sexual health consultants may be unfamiliar with the topic. 
Microbiologists, laboratory managers, senior scientific personnel and laboratory staff were 
also invited to return questionnaires, but in most cases did not do so. The reasons for this are 
unknown. The results are therefore biased in favour of those who felt able to engage with the 
questionnaire and suggest that expert knowledge of MG is limited outside the sexual health 
specialty. 
 
The high level of agreement with the majority of the statements (84.4%) indicates that 
respondents views echo those of the author group; 59.4% of the statements achieved 
agreement scores >90%. The remaining statements achieved varying levels of agreement. 
 
Although MG is associated with cervicitis [1,2] and can, therefore, potentially cause a vaginal 
discharge, three studies of women with vaginal discharge, two in a community setting and 
one among high risk sexual dyads, did not provide any evidence of an association with the 
mycoplasma. [18-20] This may explain why in “selection of patients” there was a consensus 
that women with unexplained, persistent vaginal discharge should be tested. Although it is 
biologically plausible that MG causes proctitis, there is only one large study, published in 
2016, that demonstrates an association of MG with proctitis. [22]  Further evidence of the 
association of MG with vaginal discharge, particularly in those in whom this persists despite 
standard treatment, and in men and women with proctitis, is therefore needed.   
 
With regard to the selection of patients for MG testing, early research indicated that only 2-
5% of asymptomatic individuals with C. trachomatis in the general population were co-
infected.[23-27] However, a more recent study from London suggested that co-infection 
might be as high as 9.7% in 15-19 year-old women infected by chlamydiae. [28] The earlier 
work may explain why respondents did not necessarily associate the two infections and this 
possibly reflects the low consensus for MG-testing of patients with chlamydial infection 
(50.9%). Respondents agreed that asymptomatic patients should not be tested, which may 
also explain the low consensus for MG-testing of patients with a chlamydial infection. Given 
that asymptomatic chlamydial infection in the community is often treated with azithromycin 
1g , which is associated with the development of macrolide resistance in MG, the former 
explanation is the most likely. [9, 22] 
 
There is currently no evidence to demonstrate whether screening does more good than harm 
at a reasonable cost. An important consideration when undertaking cost-effectiveness studies 
is the potential harm associated with development of anti-microbial resistance and its cost 
implications as a result of sub-optimal therapy in patients with MG who remain 
undetected .[8]  
 
High levels of antimicrobial resistance are reported and specific treatment for MG is 
therefore important. [5] To this end, test of cure is advisable irrespective of the resolution of 
symptoms, as appropriate testing to ensure that the infection has cleared in response to 
treatment is an important tool in the management of antimicrobial resistance. [7] 
Surprisingly, while responses were positive (68.3% agreement), consensus was not reached 
supporting MG-test of cure, despite this being strongly recommended in the European 
guideline. [7] Perhaps this may be because respondents disagree with routine testing of cure, 
feeling that it is unnecessary when symptoms have abated as is currently recommended for 
men with NGU following treatment in the UK and USA. [29, 30] However, patients may 
become asymptomatic but remain persistently infected. [7, 31] It is reassuring to see that 
respondents are against unwarranted use of moxifloxacin, with strong consensus (statement 
27: 93.2% agreement) reflecting concern over presumptive use, although moxifloxacin may 
be used specifically for PID according to a strong evidence base whether or not MG is 
present. [32] Almost all respondents agreed that use of 1g azithromycin should be avoided in 
the treatment of MG in order to reduce the risk of macrolide resistance. [5, 22] Currently, 
azithromycin 500mgs and then 250mgs od for 4 days is recommended to treat MG infection. 
[7, 33] While previous studies indicated that development of macrolide resistance was 
uncommon following treatment with this extended azithromycin regimen [34-36], a more 
recent retrospective study from Australia indicated a similar rate to that observed historically 
with azithromycin 1g. [13] The reason for this apparent discrepancy is unclear and further 
prospective studies are therefore indicated. This reinforces the importance of undertaking a 
test of cure following treatment. Moxifloxacin can be used in those patients who fail 
azithromycin and/or in those patients with proven MG-macrolide resistance. In view of the 
concern regarding antimicrobial resistance there was strong support for resistance testing 
which is not yet routinely available.  
Despite strong levels of agreement with the need for MG testing as advised by BASHH, it 
does not happen universally. This may be due to limitations in resources and capacity and the 
lack of awareness of the commercial availability of a NAAT for MG detection.  Future 
guidelines from BASHH may strengthen the case that sexual health clinicians can expect 
laboratories to provide MG-testing.  
 
Respondents clearly identified the following groups as having a high priority for MG-testing: 
men with symptoms of urethritis, women with symptoms of PID, women with unexplained 
persistent vaginal discharge or post-coital bleeding and current sexual contacts of MG- 
positive patients. 
 
This consensus approach has two methodological limitations; firstly, the exact number of 
clinicians invited to complete the questionnaire is unclear and thus the response rate cannot 
be calculated with any accuracy, although we estimate it to be about 30%. Secondly, the 
responders are likely to show bias in their knowledge of the management of MG infection as 
they were clearly sufficiently interested to share their opinions. However, the strong 
representation of sexual health consultants offers a useful insight to the attitudes of this group 
of professionals with regard to testing for and management of MG infection. 
 
RECOMMENDATIONS AND CONCLUSIONS 
The following six recommendations are offered on the basis of this work: 
• The following groups should be regarded as having a high priority for MG-testing: 
▪ Men with symptoms of urethritis 
▪ Women with symptoms of PID  
▪ Women with unexplained persistent vaginal discharge or post-coital 
bleeding 
▪ Current sexual contacts of MG-positive patients 
• More evidence is needed for MG as a cause of unexplained and persistent discharge in 
women  
• More evidence is needed for MG as a cause of proctitis in MSM and in women 
• A UK MG guideline is likely to facilitate the introduction of targeted MG-testing and AMR-
testing in clinical practice. Such a policy would be expected to be cost effective, but this 
remains to be demonstrated. 
• Until a UK MG guideline becomes available, closer adherence to the European guidance is 
needed 
• Test of cure is required following the use of azithromycin, and moxifloxacin used for further 
treatment if required 
KEY MESSAGES 
• Commercial availability of MG-testing presents an opportunity for improving the diagnostic 
and management pathways of several clinical syndromes associated with MG infection. 
• Clinicians should ensure that their local laboratories meet the requirements of accepted 
guidelines for MG-testing 
• Test of cure is advisable irrespective of the resolution of symptoms, to ensure that the 
infection has cleared in response to treatment 
• 1g azithromycin should be avoided in the treatment of MG infection in order to reduce the 
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